Catalyst
Slingshot members are tracking this event:
BLINCYTO (blinatumomab) Induced Complete Remission In Heavily Pretreated Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AMGN |
|
|
||||
Additional Information
Results From Exploratory Pooled Phase 1 and 2 Analysis Show BLINCYTO, the Only Bispecific T Cell Engager (BiTE®) Immunotherapy Approved in the U.S., Induced Complete Remission in Some Patients in all Pre-specified Subgroups
More Than Half of Patients who Achieved Complete Remission Also Experienced Complete Minimal Residual Disease Response
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Blincyto, Blinatumomab, Acute Lymphoblastic Leukemia
